Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jason, Sanghavi, Kinjal, Shen, Jun, Zhao, Xiaochen, Feng, Yan, Statkevich, Paul, Sheng, Jennifer, Roy, Amit, Zhu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930858/
https://www.ncbi.nlm.nih.gov/pubmed/31710163
http://dx.doi.org/10.1002/psp4.12476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930858/
https://www.ncbi.nlm.nih.gov/pubmed/31710163
http://dx.doi.org/10.1002/psp4.12476

Ejemplares similares